# A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules

> **NCT02667938** · PHASE3 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 510 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** HCP1303 capsule 5/0.2mg
- **DRUG:** HCP1303 capsule 5/0.4mg
- **DRUG:** HGP1201
- **DRUG:** HCP1303 capsule 5/0.2mg placebo
- **DRUG:** HCP1303 capsule 5/0.4mg placebo
- **DRUG:** HGP1201 placebo

## Key facts

- **NCT ID:** NCT02667938
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2016-01
- **Final completion:** 2016-05
- **Target enrollment:** 510 (ACTUAL)
- **Last updated:** 2016-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02667938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02667938, "A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02667938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*